Drug Type Fusion protein |
Synonyms- |
Target |
Action agonists |
Mechanism ADCYAP1R1 agonists(Pituitary adenylate cyclase-activating polypeptide type I receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metabolic dysfunction-associated steatotic liver disease | Preclinical | United States | 01 Apr 2019 | |
Metabolic dysfunction-associated steatotic liver disease | Preclinical | United States | 01 Apr 2019 | |
Metabolic dysfunction-associated steatotic liver disease | Preclinical | Canada | 01 Apr 2019 |